BeOne Medicines Ltd. — Director's Dealing 2022

Jul 18, 2022

SEC Form 4/A — Form 4/A

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2022-07-01

Reporting Person: Wang Julia Aijun (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-01	American Depositary Shares	S	317	$158.50	Disposed	0	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	241462	Direct

Footnotes

F1: The original Form 4, filed on July 5, 2022, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on July 1, 2022 as a total of 295 American Depositary Shares ("ADSs") sold when in fact 317 ADSs were sold. As a result of this administrative error, the number of Ordinary Shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of Ordinary Shares reported as beneficially owned by the reporting person by 286 Ordinary Shares.

F2: Each American Depositary Share represents 13 Ordinary Shares.

F3: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.